business

Tom Jones5/8/25

Flutter keeps blaming different sets of sports fans for ruining its results

After posting disappointing earnings, most companies vaguely gesture toward the wider economic climate to explain missed estimates to their demanding investors. Gambling giant Flutter Entertainment, on the other hand, has an ace up its sleeve: blame it on the prowess of the customers themselves.

In an interview with CNBC, Flutter CEO Peter Jackson circled out “customer-friendly” results in this year’s NCAA March Madness tournament — where the Final Four teams were all No. 1 seeds — to explain why the FanDuel parent company missed top- and bottom-line expectations in Q1.

At the start of the year, though, it was football fans who apparently weighed heavy on the financials of the world’s biggest online betting company, with Flutter publishing a surprise trading update pointing to the adverse effects of the NFL’s “highest rate of favorites winning in nearly 20 years.”

While DraftKings’ biggest rival is maintaining guidance for 2025, it seems like the company looking to fans’ skills and “poor sports results” to explain its own underperformance is becoming a bit of a safe bet.

March Madness drags down Flutter first-quarter results

March Madness drags down Flutter first-quarter results

In an interview with CNBC, Flutter CEO Peter Jackson circled out “customer-friendly” results in this year’s NCAA March Madness tournament — where the Final Four teams were all No. 1 seeds — to explain why the FanDuel parent company missed top- and bottom-line expectations in Q1.

At the start of the year, though, it was football fans who apparently weighed heavy on the financials of the world’s biggest online betting company, with Flutter publishing a surprise trading update pointing to the adverse effects of the NFL’s “highest rate of favorites winning in nearly 20 years.”

While DraftKings’ biggest rival is maintaining guidance for 2025, it seems like the company looking to fans’ skills and “poor sports results” to explain its own underperformance is becoming a bit of a safe bet.

More Business

See all Business

Strive Pharmacy recently broke ground on a new facility in Mesa, Arizona. (Strive Pharmacy)

Before Hims’ GLP-1 pill fallout, its pharmacy partner was already drawing scrutiny from state regulators

Strive has already been probed over the timing of its GLP-1 compounding. Now, Arizona regulators are looking into complaints about ketamine misuse and improper distribution of prescription drugs.

J. Edward Moreno2/13/26

Claire Yubin Oh

The apex operator

SharkNinja hit an all-time high this week, as its killer growth streak continues

The viral appliance maker’s sales have more than quadrupled since 2018.

Surreal image of great white shark swimming in bedroom

Claire Yubin Oh

in this econemy?

Van Leeuwen, America’s fastest-growing dessert chain, is looking to expand abroad

The boutique ice cream chain is looking to open at least 300 new shops in South Korea over the next decade.

Van Leeuwen Ice Cream Truck Los Angeles

J. Edward Moreno

Hims built a boundary-pushing health business. Now the legal risks are catching up.

Hims is close to trading as if it never began selling GLP-1s.

Hims & Hers Health CEO Andrew Dudum

business

Nate Becker2/7/26

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration.

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims & Hers Comms on X

Hims & Hers Comms on X: "Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment. We remain committed to the millions of Americans who depend on us" / X

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.

©2026 Sherwood Media, LLC